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Abstract Various signs on routine brain MRI can help
differentiate between Parkinson’s disease (PD) and the
various forms of atypical parkinsonism (AP). Here, we
evaluate what routine brain MRI contributes to the clinical
diagnosis, in both early and advanced disease stages. We
performed a prospective observational study in 113
patients with parkinsonism, but without deﬁnite diagnosis
upon inclusion. At baseline, patients received a structured
interview, comprehensive and standardized neurological
assessment, and brain MRI. The silver standard diagnosis
was made after 3 years of follow-up (PD n = 43, AP
n = 57), which was based on disease progression, repeat
standardized neurological examination and response to
treatment. The clinical diagnosis was classiﬁed as having
either ‘low certainty’ (lower than 80%) or ‘high certainty’
(80% or higher). The added diagnostic yield of baseline
MRI results were then studied relative to clinical neuro-
logical evaluation at presentation, and at follow-up. Sen-
sitivity and speciﬁcity for separating AP from PD were
calculated for all potentially distinguishing MRI abnor-
malities described previously in the literature. MRI
abnormalities showed moderate to high speciﬁcity but
limited sensitivity for the diagnosis of AP. These MRI
abnormalities contributed little over and above the clini-
cally based diagnosis, except when the clinical diagnosis
was uncertain. For these patients, presence of putaminal or
cerebellar atrophy was particularly indicative of AP.
Routine brain MRI has limited added value for differenti-
ating between PD and AP when clinical certainty is already
high, but has some diagnostic value when the clinical
diagnosis is still uncertain.
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Introduction
Differentiating Parkinson’s disease (PD) from the various
forms of atypical parkinsonism (AP), such as multiple
system atrophy (MSA), progressive supranuclear palsy
(PSP), and corticobasal syndrome (CBS) can be challeng-
ing, especially in early disease stages. Clinical diagnostic
criteria are suboptimal or only partially validated [1].
Clinical-pathological studies show that the rates of misdi-
agnosis during life can be as high as 24%, especially in
early disease stages [2–6]. However, a correct and timely
diagnosis is important for both patients (e.g., counseling)
and clinicians (e.g., being alert for development of speciﬁc
disease complications, such as nocturnal stridor in MSA). It
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DOI 10.1007/s00415-011-6280-xis, therefore, common practice to call for ancillary investiga-
tions to improve the differentiation between PD and AP.
Brain magnetic resonance imaging (MRI) is the most
widely used ancillary test, and can be used to search for
presence of, e.g., cerebrovascular disease or normal pres-
sure hydrocephalus [7].
Routine brain MRI studies, including T1, T2, T2 FLAIR
and proton density sequences, are typically normal in PD [8,
9].Incontrast,manysignshavebeendescribedforthevarious
APs, but these changes are usually seen in advanced disease
stages [10]. Well-known brain MRI abnormalities include:
putaminal atrophy and signal changes in MSA-P; atrophy of
theponsandcerebellumandthehotcrossbunsigninMSA-C;
atrophy of the midbrain in PSP; and asymmetric cortical
atrophy in CBS [8]. However, the added diagnostic value of
these brain MRI abnormalities over and above the clinical
diagnosis remains unknown.
Our objective here was to evaluate the diagnostic value
of routine brain MRI relative to the clinically based dif-
ferentiation between PD and the various forms of AP. A
speciﬁc new element was our evaluation of whether brain
MRI improved the diagnostic accuracy, taking into account
the level of certainty about the clinically based diagnosis.
For this purpose, we performed a prospective 3-year fol-
low-up study in a large cohort of patients with an uncertain
diagnosis, and used the ‘silver standard’ diagnosis at fol-
low-up (i.e., based on rate of disease progression, new
neurological signs and response to treatment) for sub-
sequent comparisons with the baseline MRI results.
Patients and methods
Study group
We performed a prospective observational study in 113
patients with various forms of parkinsonism, but without
clinically deﬁnite diagnosis upon inclusion. Inclusion cri-
teria were clinical signs and symptoms of parkinsonism.
Exclusion criteria were age under 18 years, prior brain
surgery, and unstable co-morbidity. Patients with dystonic
tremor and a normal DAT scan were excluded from the
study, using careful clinical assessment [11]. Consecutive
patients were recruited from the outpatient department of
our movement disorder center between 2003 and 2006. The
study was approved by the medical ethics committee of our
center and all participants gave written informed consent.
Study design
Patients were clinically assessed (history taking and neu-
rological examination) at baseline and after 3 years of
follow-up. All examinations were performed by one
neurologist specialized in movement disorders (WFA). The
assessments at baseline included the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS-III; assessing severity of
motor symptoms) [12], Mini-Mental State Examination
(MMSE; global cognitive status) [13], Hoehn and Yahr
staging scale (H&Y; disease severity) [14] and the clinical
effect of levodopa administration. At baseline all patients
had a brain MRI scan, IBZM-SPECT, anal sphincter EMG,
and comprehensive CSF analysis.
After completion of the study, the diagnosis at baseline
and the silver standard diagnosis at 3-year follow-up were
made during a consensus meeting with two experienced
movement disorders experts (BRB and RAJE). For the
baseline clinical diagnosis only data from the initial history
taking and neurological examination were used. All diag-
noses were made according to international diagnostic
criteria [15–20].
Our primary interest was in separating PD from the
group of AP, and therefore all various forms of AP were
grouped together. The level of diagnostic certainty after the
baseline clinical neurological examination was scored
using a visual analogue scale, ranging from 0 (completely
uncertain) to 100 (completely certain). The clinical diag-
nosis was classiﬁed as having either ‘low certainty’ (when
the clinically based rate of certainty was lower than 80%)
or ‘high certainty’ (when the clinically based rate of cer-
tainty was 80% or higher).
The silver standard diagnosis was made using the data
obtained after 3 years of follow-up data, and included rate
of disease progression, new neurological signs during
repeated neurological examination and response to treat-
ment. Again the level of diagnostic certainty was scored.
There was no inter-rater disagreement regarding the
nature of the diagnoses at baseline or after follow-up, but
there were occasionally differences regarding the level of
certainty about the diagnosis. In case of such a discrepancy,
a consensus diagnosis was made.
We hypothesized that MRI at baseline would have
additional diagnostic value for increasing the degree of
certainty of the clinical diagnosis at baseline, using the
follow-up diagnosis at 3 years as silver standard.
Brain MRI
All patients had a brain MRI at ﬁrst presentation, per-
formed on a 1 Tesla (66 patients) or 1.5 Tesla MRI scanner
(44 patients). The scanning protocols were not standard-
ized, reﬂecting daily clinical practice, and included: axial
T1 spin echo, T2 turbo spin echo, T2 FLAIR, and proton
density sequences. Half of the scanning protocols also
included a sagittal T1 or T2 image.
The brain MRI studies were evaluated in a standardized
way by two neuroradiologists (FJAM and BG) blinded to
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123the clinical symptoms and diagnosis. The signs and
abnormalities were selected based on a literature search [8–
10]. Criteria to select these abnormalities were that they
should be validated for the evaluation of parkinsonism,
able to be seen on routine brain MRI and to be easily
scored. The following MRI changes were scored: putami-
nal T2 hypo-intensity, putaminal rim sign, putaminal
atrophy, frontal lobe and parietal lobe atrophy, lateral, third
and fourth ventricle dilatation, midbrain and pontine atro-
phy, hummingbird sign, atrophy of the cerebellum and
cerebellar vermis, atrophy of the medulla oblongata, pon-
tine T2 hyperintensity and hot cross bun sign, white matter
changes and lacunar infarction. For standardization, the
scoring system proposed by Yekhlef [10] was used. White
matter changes were scored according to the age-related
white matter changes (ARWMC) criteria [21].
Statistical analysis
Inter-observer agreement was evaluated by the kappa
coefﬁcient in a sample of 60 patients. We evaluated the
discriminative power of each individual parameter. As all
parameters were dichotomous, we calculated their sensi-
tivity and speciﬁcity. Next, we used multivariate logistic
regression with forward selection to investigate whether
particular combinations of parameters would lead to better
discrimination. Such an approach results in a score con-
sisting of a weighted sum of parameters. This score is not
dichotomous; therefore, we used the area under the receiver
operation curve (AUC) to evaluate its discriminative
power. When scores are constructed on the basis of
parameter selection methods, the AUCs tend to be over-
estimated, in particular when many candidate parameters
are used (optimism). We used cross-validation to estimate
the optimism and we present both the raw AUCs and the
AUCs corrected for optimism. Subgroup analyses were
performed for patients with either short (\36 months) or
longer duration of symptoms, and also for patients with
either ‘high certainty’ or ‘low certainty’ about the initial
clinical diagnosis.
Results
Diagnoses
Thirteen patients were excluded because a diagnosis other
than PD or AP was made (n = 8) or because patients were
lost to follow-up (n = 5). One hundred patients were,
therefore, included in the ﬁnal statistical analyses.
After 3 years of follow-up, the silver standard diagnoses
were: PD (n = 43), MSA (n = 27), PSP (n = 7), LBD
(n = 1), CBS (n = 1) and vascular parkinsonism (n = 21)
(Table 1). Mean age of patients diagnosed with an AP was
higher than for patients with PD. Disease severity as
measured by UPDRS-III was slightly higher in AP.
At baseline ‘low certainty’ about the clinical diagnosis
was present in 46% of patients ultimately diagnosed with
PD after follow-up, and for 39% of patients ultimately
diagnosed with AP (p = 0.278). This was equal for
patients with short (\36 months) and longer ([36 months)
duration of symptoms at presentation. After 3 years follow-
up the ﬁnal diagnosis differed from the baseline clinical
diagnosis in 21% of patients: six patients were diagnosed
PD where they were initially diagnosed AP and 15 patients
were diagnosed AP where they were initially diagnosed
PD.
Inter-observer agreement MRI changes
Inter-observer agreement for the various MRI changes
differed. Atrophy and T2 hypo-intensity changes of the
putamen and frontal and parietal lobe atrophy showed low
inter-observer agreement (k\0.3). Good inter observer
agreement (k = 0.6–0.8) was seen for lateral ventricle
dilatation, third and fourth ventricle dilatation, humming-
bird sign, medulla oblongata atrophy and white matter
changes. The hot cross bun sign showed excellent inter-
observer agreement (k = 0.85).
Diagnostic value of combinations of MRI changes
The AUC of a combination of MRI changes for the whole
group did not exceed 0.74 (0.71 after correction for opti-
mism), whereas clinical evaluation alone resulted in an
AUC of 0.80. The combination of clinical evaluation and
Table 1 Patient characteristics
PD (n = 43) AP (n = 57)
Age (years) 59.1 (10.8)* 65.2 (8.3)*
Disease duration (months) 42.4 (37.1) 46.6 (39.7)
%\36 months symptoms 56% 42%
UPDRS-III 26.2 (13) 30.5 (15.5)
AP subtype (after follow-up of 3 years)
Multiple system atrophy – 27
Progressive supranuclear palsy – 7
Lewy body dementia – 1
Corticobasal syndrome – 1
Vascular parkinsonism – 21
Data represent mean (SD). For atypical parkinsonism subtypes the
number of patients are mentioned. P values were assessed using
Student’s t test
PD Parkinson’s disease, AP atypical parkinsonism, UPDRS-III Uni-
ﬁed Parkinson’s Disease Rating Scale motor part
* p\0.05
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123MRI changes did not lead to an increase of the AUC
(= 0.80). For patients with low certainty about the initial
clinical diagnosis, the AUC of the clinical evaluation was
0.67 (sensitivity 59% and speciﬁcity 75%, Fig. 1). For a
combination of clinical ﬁndings and MRI results, the AUC
increased to 0.81 (0.77 after correction for optimism). The
MRI parameters responsible for this additional discrimi-
native power were cerebellar and putaminal atrophy. In
patients with low certainty about the clinical diagnosis,
sensitivity increased to 68% and speciﬁcity increased to
86% for the combination of the clinical diagnosis AP and
cerebellar atrophy.
Diagnostic value of individual MRI changes
Except for atrophy of the medulla oblongata, all MRI signs
and abnormalities were seen in PD as well as AP (Table 2).
Atrophy of the midbrain, pons, cerebellum, medulla
oblongata and T2 signal intensity changes in the pons and
putamen showed high speciﬁcity for the diagnosis of AP,
but limited sensitivity. Subgroup analysis in patients with
duration of symptoms more than 36 months showed the
same high speciﬁcity and moderate to low sensitivity for
the diagnosis of AP.
For patients with low certainty about the initial clini-
cal diagnosis (42 patients) putaminal atrophy, putaminal
rim, hummingbird sign and lacunar infarction were seen
in a minority of patients with a ﬁnal diagnosis of AP, but
were not seen at all in patients with a ﬁnal diagnosis of
PD (Table 3). This results in a high positive predictive
value.
In differentiating between the different forms of atypical
parkinsonism, atrophy and signal changes of pons and
putamen were relatively speciﬁc for MSA and midbrain
atrophy was relatively speciﬁc for PSP.
Discussion
We studied the diagnostic value of routine brain MRI for
the differentiation between PD and AP. A new element of
this study was our analysis of brain MRI results relative to
the clinical diagnosis at presentation, taking into account
the degree of certainty about the initial clinical diagnosis,
and using a carefully deﬁned silver standard diagnosis
made after 3 years of follow-up by experts in the ﬁeld.
Moreover, we did not perform cerebral MRI in patients
with advanced and established disease (where the added
value is presumably more limited), but earlier in the course
of the disease when clinical certainty was lower, creating a
greater need for additional diagnostic information from
ancillary studies. To reach the silver standard diagnosis, we
followed all patients for 3 years, allowing us to make a
more certain clinical diagnosis (using repeat neurological
examination, monitoring for new disease signs, information
about disease progression, and treatment responsiveness).
Our study conﬁrms earlier reports that routine brain MRI
can identify abnormalities which have a high speciﬁcity for
diagnosing AP, but with a limited sensitivity [8, 10, 22].
These abnormalities include atrophy of the midbrain, pons,
cerebellum and medulla oblongata and T2 hypo-intensity
changes of the putamen and the hot cross bun sign. The
new ﬁnding from the present prospective follow-up study is
that the added diagnostic value of brain MRI is relatively
highest for those patients where the baseline diagnostic
certainty is lowest.
Our study also demonstrates that the clinically based
diagnosis is good, at least in the hands of experienced
movement disorders specialists. The degree of certainty
about the clinical diagnosis was more important in pre-
dicting the diagnosis at follow-up than durations of
symptoms alone. For the whole group brain MRI did not
Fig. 1 ROC analyses. a ROC
of the initial clinical evaluation
alone for patients with uncertain
initial clinical diagnosis,
resulted in an AUC of 0.67
(sensitivity 59%, speciﬁcity
75%). b ROC of the patient with
uncertain initial clinical
diagnosis and MRI showing
putaminal and cerebellar
atrophy resulted in an AUC of
0.81. Point 1 represents
cerebellar atrophy (sensitivity
68%, speciﬁcity 86%), point 2
represents putaminal atrophy
(sensitivity 59%, speciﬁcity
100%)
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123improve the differentiation between PD and AP. However,
when the degree of certainty about the clinical diagnosis
was low (\80%), brain MRI did have some added diag-
nostic value. In these patients, cerebellar and putaminal
atrophy on routine brain MRI improved the AUC for the
differentiation between PD and AP. We, therefore, con-
clude that routine brain MRI has limited added value to
clinical neurological evaluation for the differentiation
Table 2 Frequency of brain MRI abnormalities and ability of brain MRI to identify atypical parkinsonism
MRI abnormality PD N (%) AP N (%) Sensitivity % (CI) Speciﬁcity % (CI) PPV % (CI) NPV % (CI)
Putamen atrophy 3 (7) 17 (30) 30 (19–44) 93 (80–98) 85 (61–96) 51 (39–62)
Putamen T2 hypointensity 6 (14) 9 (16) 16 (8–29) 86 (71–94) 60 (33–83) 44 (33–55)
Putaminal rim 1 (2) 9 (16) 16 (8–29) 98 (86–100) 90 (54–99) 47 (37–58)
Frontal lobe atrophy 10 (23) 23 (40) 46 (33–59) 77 (61–88) 72 (55–85) 52 (39–64)
Parietal lobe atrophy 10 (23) 26 (46) 46 (33–59) 77 (61–88) 72 (55–85) 52 (39–64)
Lateral ventricle dilatation 9 (21) 25 (44) 44 (31–58) 79 (64–89) 74 (55–86) 51 (39–64)
Third ventricle dilatation 9 (21) 25 (44) 44 (31–58) 79 (64–89) 74 (55–86) 51 (39–64)
Midbrain atrophy 4 (9) 13 (23) 23 (13–36) 91 (77–97) 76 (50–92) 47 (36–58)
Hummingbird sign (N = 50) 1 (6) 6 (18) 18 (8–36) 94 (69–100) 86 (42–90) 37 (23–53)
Fourth ventricle dilatation 5 (12) 16 (28) 28 (17–42) 88 (74–96) 76 (52–91) 48 (37–60)
Pons atrophy 1 (2) 11 (19) 19 (10–32) 98 (86–100) 92 (60–100) 48 (37–59)
Pons T2 hyperintensity 5 (12) 12 (21) 21 (12–34) 88 (74–96) 70 (44–89) 46 (35–57)
Hot cross bun sign 1 (2) 4 (1) 7 (2–17) 98 (86–100) 80 (30–99) 44 (33–54)
Medulla oblongata atrophy 0 (0) 7 (12) 12 (5–24) 100 (90–100) 100 (56–100) 46 (36–57)
Cerebellar atrophy 7 (16) 24 (42) 42 (29–56) 84 (69–93) 77 (58–90) 52 (40–64)
Cerebellar vermis atrophy 2 (5) 11 (19) 19 (10–32) 95 (83–99) 85 (54–97) 47 (36–58)
Lacunar infarction 1 (2) 9 (16) 16 (8–29) 98 (86–100) 90 (54–99) 47 (37–58)
For sensitivity, speciﬁcity, PPV and NPV a 95% Conﬁdence Interval (CI) was used
PD Parkinson’s disease, AP atypical parkinsonism, PPV positive predictive value, NPV negative predictive value
Table 3 Ability of brain MRI to diagnose atypical parkinsonism in a subgroup of patients with low certainty about the initial clinical diagnosis
(\80%, n = 42)
MRI abnormality Sensitivity % Speciﬁcity % PPV % NPV %
Putamen atrophy 36 (18–59) 100 (80–100) 100 (59–100) 58 (41–75)
Putamen hypointensity 18 (6–41) 85 (61–96) 57 (20–88) 49 (31–66)
Putaminal rim 23 (9–46) 100 (80–100) 100 (46–100) 54 (37–70)
Frontal lobe atrophy 36 (18–59) 80 (56–93) 67 (35–89) 53 (35–71)
Parietal lobe atrophy 36 (18–59) 80 (56–93) 67 (35–89) 53 (35–71)
Lateral ventricle dilatation 41 (21–63) 85 (62–96) 75 (42–93) 57 (38–74)
Third ventricle dilatation 36 (18–53) 80 (56–93) 67 (35–89) 53 (35–71)
Midbrain atrophy 23 (9–46) 95 (73–100) 83 (36–99) 53 (36–69)
Hummingbird sign (N = 22) 13 (2–42) 100 (56–100) 100 (20–100) 35 (16–59)
Fourth ventricle dilatation 14 (4–36) 90 (7–98) 60 (17–93) 49 (32–65)
Pons atrophy 9 (2–31) 95 (73–100) 67 (13–98) 49 (33–65)
Pons hyperintensity 18 (6–41) 90 (67–98) 67 (24–94) 50 (33–67)
Hot cross bun sign 5 (0–25) 95 (73–100) 50 (3–97) 48 (32–64)
Medulla oblongata atrophy 5 (2–25) 100 (80–100) 100 (5–100) 49 (33–65)
Cerebellar atrophy 45 (25–67) 85 (61–96) 77 (46–94) 59 (39–76)
Cerebellar vermis atrophy 18 (6–41) 95 (73–100) 80 (30–99) 51 (35–68)
Lacunar infarction 27 (12–50) 100 (80–100) 100 (52–100) 56 (38–72)
For sensitivity, speciﬁcity, PPV and NPV a 95% Conﬁdence Interval (CI) was used
PPV positive predictive value, NPV negative predictive value
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123between PD and AP, except when there is uncertainty
about the clinical diagnosis. A practical implication is that
in clinical practice, brain MRI should be reserved for those
patients with an ambiguous clinical presentation. This
could lead to substantial cost reductions, because various
clinical guidelines recommend a more or less standard use
of cerebral MRI for all patients presenting with parkin-
sonism [23].
The proportions of patients with a diagnosis of either PD
or AP in our study population is different from what would
be expected based on published work. The high proportion
of MSA patients is a reﬂection of the tertiary nature of our
referral centre, which is a national centre of excellence for
movement disorders, so relatively more cases of atypical
parkinsonism would be expected compared to the general
population. Since our centre is also part of the European
MSA consortium, we attract relatively many patients with
MSA. So the proportions of PD and AP seen in our centre
do not represent an accurate epidemiological estimate, but
this is not problematic for the purpose of our present study,
which is to separate AP from PD. For this purpose, we
needed a sufﬁciently large group of patients with AP.
There are some limitations to our study. First, patients
were scanned on a 1 or 1.5 Tesla MRI, and we cannot
exclude that standard use of 1.5 or 3 Tesla MRI studies
might have better diagnostic accuracy [22, 30]. However,
use of 1 or 1.5 Tesla MRI scans represents daily clinical
neurological practice in most hospitals. Moreover, there
was no signiﬁcant difference for the calculated sensitivity
or speciﬁcity for the patients scanned on a 1 and 1.5 Tesla
MRI scanner. Second, inter-observer agreement differed
for the various MRI changes. Low inter-observer agree-
ment was seen for T2 hypointensity changes and atrophy of
the putamen, probably because of low spatial resolution of
the 1 Tesla MRI studies, and because of the relative sub-
jectivity in scoring these abnormalities. Third, we did not
have post-mortem brain examination to reach a ﬁnal gold
standard diagnosis. However, we can reasonably argue that
our ﬁnal diagnosis approached the optimal diagnosis one
can reach during life. Speciﬁcally, the ﬁnal diagnosis was
made during a consensus meeting between two experi-
enced movement disorder specialists, and was based upon
an extensive neurological examination (performed by a
single neurologist in all patients) after a clinical follow-up
of 3 years. This also provided information about the rate of
progression and the effectiveness of dopaminergic medi-
cation. Although high rates of misdiagnosis have been
reported for the clinical diagnosis, recent pathological
studies show high accuracy levels ([90%) for the clinical
diagnosis when the diagnosis was made by movement
disorder specialist after a minimal follow-up of 2 years [3].
Diagnostic accuracy can be improved by modifying con-
ventional sequences or applying advanced MRI techniques.
Sensitivity of MRI changes may increase by using T2*-
weighted gradient echo sequences, susceptibility weighted
imaging (SWI) [24, 25] or by using inversion recovery
sequences [26]. Furthermore the use of a 3 or 7 Tesla MRI
scanner probably is of more diagnostic value. Using 3 Tesla
scans,aputaminalrimisanormalﬁndingandnotindicativeof
AP [27]. The diagnostic value of the putaminal rim sign as
presented above should therefore be interpreted with caution,
taking into account the ﬁeld strength of the MRI scanner.
Other work suggested that particularly diffusion weighted
imaging (DWI) improves the diagnostic accuracy to differ-
entiate between PD and AP [28–32]. The value of other
advancedMRItechniquesarediffusiontensorimaging(DTI),
magnetization transfer imaging (MTI), magnetic resonance
spectroscopy(MRS)andfunctionalMRI(BOLD)needstobe
established.
Most of these advanced MRI techniques have thus far
been studied in patients with advanced disease where the
diagnosis is already clear using clinical examination alone.
The challenge now is to apply these novel techniques to
large cohorts of patients in early disease stages where cli-
nicians are uncertain about the diagnosis, and to correlate
the baseline ﬁndings to the silver (or even gold) standard
diagnosis at follow-up, as we did in the present study.
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